initial public offerings (IPOs) trading on American exchanges

Tuesday, December 17, 2013

Veracyte (VCYT) began trading on the NASDAQ on 30 October 2013


Description

Veracyte, Inc. is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis. The Company discovers, develops and commercializes molecular diagnostic solutions that enable physicians to make informed treatment decisions early, thus helping patients avoid unnecessary invasive procedures The Company’s first commercial solution is Afirma Thyroid FNA Analysis which include Gene Expression Classifier (GEC). The GEC employs a 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The Company operates in South San Francisco, California and Austin, Texas.

Address

Suite 250, 7000 Shoreline Court
SOUTH SAN FRANCISCO, CA 94080
United States

Website 

www.veracyte.com

Key stats and ratios

Q2 (Jun '13)2012
Net profit margin-128.06%-160.38%
Operating margin-106.89%-162.79%
EBITD margin--156.72%
Return on average assets-132.35%-126.36%
Return on average equity--
Employees107

No comments:

Post a Comment